NCT00653003已完成1 期
To Compare the Relative Bioavailability of Leflunomide 20mg Tablets (Kali) With That of ARAVA 20mg Tablets(Aventis) Under Fed Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 62
- 主要终点
- Rate and Extend of Absorption
研究概览
简要总结
To compare the single-dose Bioavailability of Kali and Aventis
详细描述
To compare the relative Bioavailability of leflunomide 20mg tablets with that of ARAVA 20mg tablets in healthy female subjects under fed conditions
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Subjects will meet all of the following criteria within 30 days prior to first drug administration(except inclusion #8)
- •Healthy, surgically sterile (hysterectomy, bilateral oophorectomy) or postmenopausal (for al least 1 year)female subjects, 18 to 65 years of age(inclusive)
- •Indicate non-child bearing status by one of the following criteria:
- •Indication of successful hysterectomy. No spontaneous menses for al least 1 year, must have luteinizing hormone (LH) and follicle stimulating hormone(FSH) levels within postmenopausal range.
- •Indication of successful bilateral oophorectomy.
- •Body weight within 20% of the appropriate weight for the subject's height and frame (as published in the 1983 Metropolitan Life Insurance Company Scale, Statistical Bureau)
- •Negative for:
- •HIV Hepatitis B surface antigen and Hepatitis C antibody Urine tests for drugs of abuse (marijuana, amphetamines, barbiturates, cocaine, opiates, benzodiazepines and methadone).
- •Serum HCG consistent with pregnancy.
- •No significant disease or clinically significant findings in a physical examination.
- •No clinically significant findings in vital signs measurements and a 12-lead electrocardiogram(ECG)
- •Subjects who have received leflunomide within 4 months must have an A77-1726(Metabolite) level below 0.01ug/ml and no subsequent administration of leflunomide since that test. Note: The 30 day screening limit does not apply to this inclusion criterion.
- •Be informed of the nature of the study and given written consent prior to receiving any study procedures.
排除标准
- •Subject fulfilling any of the following criteria will be excluded from the study.
- •Known history or presence of any clinically significant medical condition.
- •Known or suspected carcinoma.
- •Known history or presence of:
- •Hypersensitivity or idiosyncratic reaction to leflunomide and/or any other drug substances with similar activity.
- •Alcoholism within the last 12 months.
- •Drug dependence and/ or substance abuse.
- •On a special diet within 4 weeks prior to drug administration(e.g. liquid, protein, raw food diet).
- •Participated in another clinical trail or received an investigational product 30 days prior to drug administration.
- •Donated up to 250 ml of blood in the past 45 days OR donated from 250 ml to 500 ml in the past 45 days OR donated 501 ml or more of blood in the past 56 days (based on the Canadian Blood Services guideline for blood donation).
- •Requirement of any medication (prescription and/ or over-the-counter) on a routine basis, with the exception of hormonal replacement therapy, nutritional supplements and/or occasional use of common analgesics.
- •Difficulty fasting or consuming the standard meals.
研究组 & 干预措施
A
Experimental
Subjects received Kali formulated product under fed conditions
干预措施: Leflunomide (Drug)
B
Active Comparator
Subjects received Aventis formulated products under fed conditions
干预措施: ARAVA (Drug)
结局指标
主要结局
Rate and Extend of Absorption
时间窗: 24 Hours
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Bioavailability Study of Leflunomide Tablets Under Fasting ConditionsTo Determine the Bioequivalence Study Under FastingNCT00652665Par Pharmaceutical, Inc.52
已完成
1 期
A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT®, a CREMOPHOR® EL-free Lipid Emulsion, and SANDIMMUNE® Injection (a Suspension of Cyclosporine in CREMOPHOR® EL) in Healthy VolunteersHealthyNCT01692834NeuroVive Pharmaceutical AB65
已完成
1 期
Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.AsthmaNCT01494610GlaxoSmithKline60
已完成
1 期
Bioavailability Study of Metronidazole Capsules Under Fed ConditionsTo Determine the Bioequivalence Study Under FedNCT01380522Par Pharmaceutical, Inc.18
已完成
1 期
Bioavailability Study of Metronidazole Capsules Under Fasting ConditionsTo Determine the Bioequivalence Study Under FastingNCT01380509Par Pharmaceutical, Inc.28